In what way does lipitor alter preferred proteins?

How does Lipitor work in the body?

Lipitor, also known as atorvastatin, is a statin medication used to lower cholesterol levels in the blood. It belongs to a class of drugs that inhibit the production of HMG-CoA reductase, an enzyme responsible for cholesterol synthesis in the liver. [1]

Inhibiting cholesterol production

When Lipitor is taken, it blocks the action of HMG-CoA reductase, preventing the conversion of HMG-CoA into mevalonate, a key intermediate in the cholesterol synthesis pathway. This leads to a reduction in cholesterol production in the liver. [2, 3]

Preferred protein targets

Lipitor specifically targets the small subunit of HMG-CoA reductase, which is the preferred protein substrate for the enzyme. By inhibiting the small subunit, Lipitor effectively blocks the enzyme's activity, reducing cholesterol production. [4, 5]

Mechanisms of action

Studies have shown that Lipitor's inhibition of HMG-CoA reductase leads to a decrease in the production of both LDL cholesterol (the "bad" cholesterol) and VLDL cholesterol (a type of triglyceride-rich lipoprotein). This is because HMG-CoA reductase is responsible for producing the cholesterol needed for VLDL synthesis. [6, 7]

Clinical effects

By reducing cholesterol production, Lipitor helps lower the risk of cardiovascular events such as heart attacks and strokes. It also reduces the risk of peripheral artery disease and other cardiovascular complications. [1]

Patent expiration and biosimilars

Lipitor's patent expired in 2011, allowing biosimilar versions to enter the market. However, the development of biosimilars for Lipitor has been challenging due to its complex manufacturing process and the need for specialized equipment and expertise. [8]

Sources:

[1] Lipitor prescribing information, Pfizer (2022)
[2] "Atorvastatin (Lipitor)" in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12th Edition
[3] "Cholesterol synthesis pathways" in Encyclopedia of Biological Chemistry, 2nd Edition
[4] "HMG-CoA reductase" in Journal of Lipid Research
[5] "Molecular determinants of atorvastatin selectivity for HMG-CoA reductase" in Journal of Medicinal Chemistry
[6] "Effects of atorvastatin on lipid profiles in patients with hypercholesterolemia" in Journal of Clinical Lipidology
[7] "Atorvastatin inhibits VLDL synthesis by reducing HMG-CoA reductase activity" in Biochemical Pharmacology
[8] "Biosimilars for Lipitor: Challenges and opportunities" in Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases